Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Healthy
Interventions: vepdegestrant, esomeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: Atumelnant, Carbamazepine, Midazolam, Digoxin, Metformin; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Candidiasis, HIV Infections
Interventions: Methadone hydrochloride, Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Ototoxicity, Drug-Induced
Interventions: ORC-13661, Placebo; Drug
Lead sponsor: Kevin Winthrop; Other
Eligibility: 18 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more

Conditions: Crohn Disease, Ulcerative Colitis
Interventions: Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Cypress, California • Miami Springs, Florida • Durham, North Carolina

Conditions: White Coat Hypertension, Hypertension, Blood Pressure, Anxiety, Virtual Reality Exposure Therapy, Ambulatory Blood Pressure Monitoring, Blood Pressure Disorders
Interventions: Virtual Reality Exposure; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Healthy Volunteers
Interventions: PRT064445/Apixaban, Placebo/Apixaban, Placebo; Combination Product · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Cancer, Cardiotoxicity
Interventions: Exercise program; Other
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 9 Years to 99 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Hartford, Connecticut • Columbus, Ohio

Conditions: Cardiovascular Diseases
Interventions: Quantra QPlus System; Diagnostic Test
Lead sponsor: HemoSonics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Prescott, Arizona

Conditions: Testicular Neoplasms
Interventions: Questionnaire; Behavioral
Lead sponsor: Lawrence Einhorn; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Methamphetamine Use Disorder
Interventions: Methamphetamine, Methylphenidate, Placebo oral capsule, Duloxetine; Drug
Lead sponsor: Craig Rush; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Treatment Resistant Depression
Interventions: Lithium, Placebo, Ketamine; Drug
Lead sponsor: William V. Bobo, M.D.; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Drug Effects
Interventions: [11C] desmethyl-loperamide, Control - no pretreatment, Oral ritonavir, Oral efavirenz; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Solid Tumors
Interventions: palifosfamide-tris, Normal Saline; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Dallas, Texas • Houston, Texas • San Antonio, Texas

Conditions: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
Interventions: rosiglitazone, XL184; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • The Bronx, New York + 2 more

Conditions: Drug-drug Interaction
Interventions: rifampin IV, Rifadin 300Mg Capsule, Fluvastatin 20 MG; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteer
Interventions: Ethinyl Estradiol + Levonorgestrel, ABBV-722; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Pain, Cannabis, Opioid Use
Interventions: Within-subject test of blinded study medications; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Drug Related Problems Post Hospital Discharge, Healthcare Utilization, Discharge Medication Counseling
Interventions: RPh Counseling + Outpatient Med Dispensing at Discharge, Discharge Med Dispensing Plus Counseling - Current Practice; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Subjects, Drug Interactions, Pharmacokinetics of ASP015K
Interventions: ASP015K, Mycophenolate Mofetil; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Healthy Participants
Interventions: BMS-986196, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prevention of Chemotherapy-induced Myelosuppression
Interventions: ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2); Drug
Lead sponsor: Aileron Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 5
States / cities: Tamarac, Florida • Huntersville, North Carolina • Wilson, North Carolina + 2 more

Conditions: Renal Cell Cancer, Prostate Cancer, Effects of Chemotherapy
Interventions: CORA- Device:smartphones"; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Virtual Reality as a Tool to Lower Blood Pressure and Anxiety in Clinic Settings

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy

Use of the Quantra QPlus Sytem in Cardiac Surgery

The Platinum Study Comparison Group

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

Efavirenz and Ritonavir on Human Brain P-Glycoprotein

Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Drug-Drug Interaction Between Rifampin and Fluvastatin

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

Enhancing Medication-based Analgesia in Humans- STUDY 2

Drug-Related Problems and Healthcare Utilization Post-Hospital Discharge

Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers

Observational Trial of the Longitudinal Effects of CFTR Modulator Drugs

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention